Skip to main content
letter
. 2020 Feb 3;13:117–121. doi: 10.2147/CCID.S233097

Figure 1.

Figure 1

Patient disposition.

Notes: aPatients were still included in the analysis and enrolled in long-term follow-up due to completion of most of the treatment period. bOne patient was excluded from efficacy analysis due to receipt of placebo in 5 of 13 doses.

Abbreviation: BCC, basal cell carcinoma.